Health Condition 1: N186- End stage renal disease
Conditions
Interventions
Intervention1: Sacubitril/Valsartan: Angiotensin receptor- Neprilysin inhibitor
Intervention2: Sacubitril/Valsartan: Sacubitril/Valsartan is a angiotensin receptor blocker-neprilysin inhibitor combina
Sponsors
Postgraduate Institute of Medical Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: Patients declared as CKD 5D Aged >18 years Resistant hypertension Non oliguric Definitions CKD 5D- defined as hemodialysis dependence since last 3 months prior to screening Resistant hypertension- defined as uncontrolled hypertension SBP > 140 mm Hg or DBP >90 mm Hg despite use of 3 or more antihypertensive drugs including a diuretic Non oliguric- defined as urine output more than 200 ml per day
Exclusion criteria
Exclusion criteria: Serum potassium >5.5 mg/dl Not giving consent History of angioedema History of intolerance to ACE-inhibitors/ ARBs Associated heart failure with reduced ejection fraction Alanine aminotransferase or Aspartate aminotransferase >2 times the upper limit of the normal range Not willing for thrice a week hemodialysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The safety of Sacubitril/Valsartan in CKD 5D patientsTimepoint: at the end of week-1/2/4/8/12 | — |
Secondary
| Measure | Time frame |
|---|---|
| To study efficacy of Sacubitril/Valsartan in control of resistant hypertension in CKD 5D patientsTimepoint: at the end of 3 months | — |
Countries
India
Contacts
Public ContactDr Manish Rathi
PGIMER Chandigarh
Outcome results
None listed